Mersana Therapeutics (MRSN) Stock Price, News & Analysis

Company Overview

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $6.82 to $7.72
• 50-Day Range: $5.97 to $10.18
• 52-Week Range: $5.21 to $70.75
• Volume: 226,499 shs
• Average Volume: 130,465 shs
• Market Capitalization: $37.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.60
• Consensus Rating: Buy

Mersana Therapeutics Stock Analysis - MarketRank™

Mersana Therapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 105th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Mersana Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Mersana Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Mersana Therapeutics are expected to decrease in the coming year, from ($0.62) to ($0.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mersana Therapeutics is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mersana Therapeutics is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.01% of the float of Mersana Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Mersana Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mersana Therapeutics has recently decreased by 94.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mersana Therapeutics does not currently pay a dividend.

Dividend Growth

Mersana Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -0.69

Percentage of Shares Shorted

8.01% of the float of Mersana Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Mersana Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mersana Therapeutics has recently decreased by 94.96%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.06

News Sentiment

Mersana Therapeutics has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Mersana Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 6 people have searched for MRSN on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Mersana Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mersana Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.00% of the stock of Mersana Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

93.92% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MRSN Stock Analysis - Frequently Asked Questions

How have MRSN shares performed this year?

Mersana Therapeutics' stock was trading at $35.75 on January 1st, 2025. Since then, MRSN shares have decreased by 79.2% and is now trading at $7.42.

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) released its earnings results on Wednesday, August, 13th. The company reported ($4.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.75) by $0.33. The company had revenue of $3.06 million for the quarter, compared to the consensus estimate of $6.06 million. Mersana Therapeutics had a negative net margin of 217.63% and a negative trailing twelve-month return on equity of 990.16%.
Read the conference call transcript.

When did Mersana Therapeutics' stock split?

Mersana Therapeutics's stock reverse split on the morning of Friday, July 25th 2025.The 1-25 reverse split was announced on Thursday, July 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Mersana Therapeutics IPO?

Mersana Therapeutics (MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Mersana Therapeutics' major shareholders?

Top institutional shareholders of Mersana Therapeutics include Geode Capital Management LLC (21.03%), Cerity Partners LLC (6.43%), Marshall Wace LLP (4.55%) and Qube Research & Technologies Ltd (3.06%). Insiders that own company stock include Timothy B Lowinger, Anna Protopapas, Martin H Jr Huber, Brian Deschuytner, Alejandra Carvajal, Ashish Mandelia, Mohan Bala, Arvin Yang and Tushar Misra.
View institutional ownership trends.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mersana Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mersana Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Saia (SAIA), Rambus (RMBS), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MRSN
• CIK: 1442836
• Web: www.mersana.com
• Phone: (617) 498-0020
• Fax: N/A
• Employees: 150
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Mersana Therapeutics: $56.60
• High Price Target: $125.00
• Low Price Target: $17.00
• Potential Upside/Downside: +662.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($14.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.19 million
• Net Margins: -217.63%
• Pretax Margin: -216.41%
• Return on Equity: -990.16%
• Return on Assets: -48.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.83
• Quick Ratio: 1.83

Sales & Book Value

• Annual Sales: $40.50 million
• Price / Sales: 0.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.92) per share
• Price / Book: -3.86

Miscellaneous

• Outstanding Shares: 4,990,000
• Free Float: 4,337,000
• Market Cap: $37.03 million
• Optionable: Optionable
• Beta: 0.83